SGLT2 inhibitors + mineralocorticoid receptor antagonists
1 paper3 findings
- 1 lab in 1 country
- Humans1
Outcomes
1renin-angiotensin-aldosterone system
upin humans1
1 study
renin-angiotensin-aldosterone system
upin humans1
SGLT2 inhibitors + mineralocorticoid receptor antagonists activate renin-angiotensin-aldosterone system in humans.
“Groups A and B showed activation of the renin-angiotensin-aldosterone system”
HumansHeart failure; initiation of combined therapy (Group A)30 days
International journal of molecular sciences24 Sep 2026
Associations
2Urinary albumin excretion
downin humans1
1 study
Urinary albumin excretion
downin humans1
SGLT2 inhibitors + mineralocorticoid receptor antagonists are associated with urinary albumin excretion in humans.
“Group A exhibited increased 24 h urinary sodium and chloride excretion and lower urinary albumin excretion.”
HumansHeart failure; initiation of combined therapy (Group A)30 days
International journal of molecular sciences24 Sep 2026
24-hour urinary sodium and chloride excretion
upin humans1
1 study
24-hour urinary sodium and chloride excretion
upin humans1
SGLT2 inhibitors + mineralocorticoid receptor antagonists are associated with 24-hour urinary sodium and chloride excretion in humans.
“Group A exhibited increased 24 h urinary sodium and chloride excretion and lower urinary albumin excretion.”
HumansHeart failure; initiation of combined therapy (Group A)30 days
International journal of molecular sciences24 Sep 2026